Question 1

What is Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense?

Accepted Answer

Trevi Therapeutics, Inc. (TRVI) reported operating lease right-of-use assets amortization expense of $105K in Q1 2026.

Question 2

How has Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense changed year-over-year?

Accepted Answer

Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense decreased by 6.3% year-over-year, from $112K to $105K.

Question 3

What does operating lease right-of-use assets amortization expense mean?

Accepted Answer

The periodic expense recognized for the consumption of the economic benefits of right-of-use assets related to operating leases. This reflects the systematic allocation of the asset's cost over the lease term. It is a standard accounting measure for companies with significant leased office or laboratory space.

Line item	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Net loss	$(13,192)	$(10,340)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,191	1,208
Operating lease right-of-use assets	105	112
Depreciation and amortization	34	37
Accretion of available-for-sale marketable securities, net	(431)	(395)
Changes in operating assets and liabilities:
Accrued expenses and other liabilities	(1,075)	(1,501)

Operating lease right-of-use assets amortization expense at other companies

Other financials

Income statement

Balance sheet

Cash flow

Valuation

Returns & leverage

Where this comes from

FAQ

Ask your AI about Trevi Therapeutics, Inc.'s operating lease right-of-use assets amortization expense.

Trevi Therapeutics, Inc. TRVI Operating lease right-of-use assets amortization expense